

ForPatients

by Roche

Diabetic Macular Edema Uveitic Macular Edema

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT06771271 BP40899

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study was to assess the safety and tolerability of RO7200220 as monotherapy (diabetic macular edema [DME] or uveitic macular edema [UME] population) and in combination with ranibizumab (DME population only).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT06771271 BP40899
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
